- The bulls were charged on the NFP miss and central bank convergences.
- AUD/USD bulls are up against a wall of resistance on RBA week.
The doves are swooping down on the Federal Reserve and hawks are gathering pace elsewhere, such as at the European Central Bank.
Convergence between central banks is knocking the air out of the greenback and blowing it back into the commodity complex instead.
Short covering is the name of the game as US dollar longs are squeezed which is giving rise to a rally in risk, including the Aussie dollar which had a relentless daily run last week of over 2.6% vs USD.
The US August Labour report provided additional support, as the data have implications for when the Fed will announce a bond market taper.
The September Fed meeting is no longer expected to announce timings of tapering, but more than likely highlight the lack of duality between a taper and a rate hike.
Meanwhile, the debate over the ECB's next step continues following higher inflation readings and hawkish rhetoric from particular ECB officials.
''The odds of the ECB reducing the Pandemic Emergency Purchase Programme (PEPP) are rising, and even a small tweak here could pacify the hawks such as Knot and Holzmann,'' analysts at Brown Brothers Harriman explained.
''We assume this is not priced in –certainly not fully priced – so it would lead to another leg higher in the euro if materialized,'' the analysts said, and likely lend support to other risk currencies, such as AUD.
AUD/USD's rally has happened despite the lockdowns.
In actual fact, the bulls were probably enthused by the news of a deal with the UK to secure four million doses of Pfizer.
Prime Minister Scott Morrison last week announced the deal would add 4 million Pfizer doses to Australia's supplies, doubling the nation's Pfizer supply this month.
The first flight from London was carrying 164,970 doses landed on Sunday evening while the second, carrying 292,500 doses, arrived a few hours later.
Deputy Chief Medical Officer Sonya Bennett said the extra vaccines had bolstered the vaccine rollout which should be reassuring for financial markets in APAC this week.
This is especially key on a week when the Reserve Bank of Australia is set to meet on 7 Sep.
See the FXStreet calendar
However, the general consensus was that as new infections in Australia continue to rise despite the lockdowns until the vaccination rollout gathers steam, the Reserve Bank of Australia (RBA) would be expected to delay its QE tapering (AUD 5bn to 4bn/month).
The taper plan was announced back in early July and scheduled to start in September.
With all that being said, the round of data of late has been surprisingly strong, but the RBA might want to wait for the third-quarter results before pulling the trigger.
Supporting the currency, the economy of Australia expanded 0.7% QoQ, beating the consensus forecast of 0.4%, and the trade surplus in July widened to a record high of A$12.1bn in July on the back of higher exports of LNG, coal and iron ore.
AUD/USD technical analysis
The bulls will need to get through this current level of resistance beyond the 0.7480s or face pressures back to test the old resistance block as a fresh support structure.
The support comes in near the 38.2% Fibonacci and 50% mean reversion slightly below between 0.7380 and 0.74 the figure.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.